https://www.selleckchem.com/products/sel120.html
g., the Stamey scale in 5 studies). The pooled objective treatment success rate was 7.0 % (95 % CI 59.0.0 %-75.0 %; I2 82.4 %) and 46.0 % (95 % CI 37.0 %-55.0 %; I2 55.3 %) in women with a follow-up of ≤12 and 12 months, respectively. The percentage of adverse events was 0.4 % (vaginal infection, irritation, lichen sclerosus, worsening urinary incontinence). However, the use of UBAs as the first-line therapy should be demonstrated in more comparative studies (randomized studies MUSs vs. UBAs). UBAs should be considered a first-line s
Like
Comment
Share
